Abstracts tagged "Mortality"

Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Ines Perez - Sancristobal¹, Dalifer Freites¹, Leticia Lopez Pedraza², Maria Paula Alvarez Hernandez¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez¹, Cristina Vadillo¹, Luis Rodriguez Rodriguez⁴, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁵, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…
Abstract Number: 0290 • ACR Convergence 2021
Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
Didem Sahin Eroglu¹, Anil Colaklar², Serdar Baysal³, Murat Torgutalp¹, Asaf Baygul⁴, Serdar Sezer¹, Emine Aydemir Guloksuz¹, Mehmet Yuksel¹, Mucteba Yayla¹, Emine Uslu yurteri⁵, Caglar Uzun², Ozlem Ozdemir kumbasar⁴, Murat Turgay¹, Kinikli Gulay¹ and Askin Ates¹, ¹Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Ankara University Faculty of Medicine, Department of Radiology, Ankara, Turkey, ³Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴Ankara University Faculty of Medicine, Department of Pulmonology, Ankara, Turkey, ⁵Hatay Training and Research Hospital, Hatay, Turkey
Background/Purpose: Rheumatoid arthritis-related lung disease (RA-LD) is a common manifestation of rheumatoid arthritis (RA) and associated with excess mortality. Many studies to date were focused…
Abstract Number: 0937 • ACR Convergence 2021
Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
Gino Chesini¹, Elizabeth Parrott¹, Lauren Fox¹, Jenna Beatty¹, Cassandra Effken¹, Na Yu¹, Florence Hosseini-Aslinia¹ and Megan Krause², ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Inflammatory bowel disease (IBD) causes a wide range of symptomology frequently leading to co-management of disease activity between gastroenterologist and rheumatologists. Recently in efforts…
Abstract Number: 1561 • ACR Convergence 2021
Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic
Jennifer Santana Peralta de Heyaime, Teresandris Polanco Mora, Angelo Cornelio Vasquez, Yamilet Cruz, Edral Rodriguez, Tirso Valdez Lorie, Roberto Munoz and Rafael Alba Feriz, Hospital Docente Padre Billini, Santo Domingo, Dominican Republic
Background/Purpose: SARS-CoV-2 infection is caused by a new coronavirus. The World Health Organization (WHO) had information about the existence of this new virus on December…
Abstract Number: 0339 • ACR Convergence 2021
Trends in Disparity by Age, Sex and Race for Systemic Lupus Erythematosus Patients
Anum Akhlaq¹ and Abdul Mannan Khan Minhas², ¹Orange Park Medical Center, Orange Park, FL, ²Forrest General Hospital, Hattiesburg
Background/Purpose: Important disparities in SLE patients persist based on their sex and racial/ethnic status. The aim of this study is to examine the trends in…
Abstract Number: 0954 • ACR Convergence 2021
The Association of Rituximab- vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis
Zachary Wallace¹, Xiaoqing Fu², Claire Cook³, Yuqing Zhang⁴, John Stone⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Lexington, MA
Background/Purpose: The RAVE trial established the non-inferiority of rituximab (RTX) vs cyclophosphamide (CYC) for remission induction of ANCA-Associated Vasculitis (AAV). Patients in RAVE were followed…
Abstract Number: 1629 • ACR Convergence 2021
Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
Vivian Saper¹, Sampath Prahalad², Scott Canna³, Rabheh Abdul-Aziz⁴, Marcela Alvarez⁵, Catherine Bingham⁶, Brigitte Bader-Meunier⁷, Imelda Balboni⁸, Roberta Berard⁹, Roxana Bolaria¹⁰, Alexis Boneparth¹¹, Alicia Casey¹², Elaine Cassidy¹³, Joyce C. Chang¹⁴, Michal Cidon¹⁵, Kathleen Collins¹⁶, Aileen M. Dickenson¹⁷, Graciela Espada⁵, Martha Fishman¹², Elaine Flanagan¹⁸, Timothy Hahn¹⁹, Ankur K. Jindal²⁰, Ozgur Kasapcopur²¹, Marisa Klein-Gitelman²², Timothy Klouda¹², Mikhail Kostik²³, Carol Lake²⁴, Mariana Marques²⁵, Michael Ombrello²⁶, Karen Onel²⁷, Omkar Phadke²⁸, Angelo Ravelli²⁹, Adam Reinhardt³⁰, Amanda D. Robinson³¹, Kelly Rouster-Stevens³², Nadine Saad²⁷, Grant Schulert³³, Susan Shenoi³⁴, Cory Stingl¹⁴, Anjali Sura³⁵, Melissa Tesher³⁶, Jessica Tibaldi³⁷, Kathryn Torok³⁸, Cathy Tsin³⁹, Natalia Vasquez-Canizares⁴⁰, D. Sofia Villacis-Nunez⁴¹, Ben Whitehead⁴², Holly Wobma¹², Lawrence Zemel⁴³ and Elizabeth Mellins¹, ¹Stanford University, Stanford, CA, ²Emory + Children's Pediatric Institute, Atlanta, GA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University at Buffalo, Buffalo, NY, ⁵Hospital de Niños Dr Ricardo Gutierrez, Buenos Aires, Argentina, ⁶Penn State Children's Hospital, Allentown, PA, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Stanford University, Palo Alto, CA, ⁹London Health Sciences Centre, London, ON, Canada, ¹⁰Self, Victoria, BC, Canada, ¹¹Columbia University Medical Center, New York, NY, ¹²Boston Children's Hospital, Boston, MA, ¹³University of Pittsburgh Medical Center Medical Education, Pittsburgh, PA, ¹⁴Children's Hospital of Phildelphia, Philadelphia, PA, ¹⁵Children's Hospital Los Angeles, Los Angeles, CA, ¹⁶LeBonheur Children's Hospital, Memphis, TN, ¹⁷Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁸Emory University and Children's Healthcare of Atlanta, Atlanta, GA, ¹⁹Penn State Childrens Hospital, Hershey, PA, ²⁰Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ²²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴National Institutes of Health, Gaithersburg, MD, ²⁵UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, ²⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²⁷Hospital for Special Surgery, New York, NY, ²⁸EMORY, Atlanta, GA, ²⁹Istituto Giannina Gaslini, Genoa, Italy, ³⁰Boys Town National Research Hospital, Omaha, NE, ³¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁴Seattle Children's Hospital, Seattle, WA, ³⁵SUNY Upstate Medical University, Syracuse, NY, ³⁶University of Chicago, Chicago, IL, ³⁷IRCSS Istituto G. Gaslini University of Genoa, Genoa, Italy, ³⁸University of Pittsburgh, Pittsburgh, PA, ³⁹Stanford University, Stanford, ⁴⁰Children's Hospital at Montefiore, Bronx, NY, ⁴¹Children's Healthcare of Atlanta - Emory University, Atlanta, GA, ⁴²Queensland Children's Hospital, Brisbane, Australia, ⁴³CCMC, Hartford, CT
Background/Purpose: Severe delayed hypersensitivity reactions (DHR) are under-recognized in inflammatory conditions, particularly drug reaction with eosinophilia and systemic symptoms (DRESS). Previous work has shown this…
Abstract Number: 0409 • ACR Convergence 2021
Factors Predicting Mortality in an Indian Cohort of Systemic Sclerosis
T G Sundaram¹, Durga P Misra¹, Rudrarpan Chatterjee¹, Sakir Ahmed² and Vikas Agarwal³, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Kalinga Institute of Medical Sciences, Bhubaneswar, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Systemic sclerosis is characterised by high morbidity and mortality due to disease-related or treatment-related complications.Methods: Data of patients of systemic sclerosis between 1990 and…
Abstract Number: 1028 • ACR Convergence 2021
Knee Osteoarthritis and Mortality: The Osteoarthritic Initiative
Jane Cauley¹, Michael Nevitt², Kai Sun³, Jason Maeda³, C. Kent Kwoh⁴, Leena Sharma⁵, Rebecca Jackson⁶, Susan Rubin³ and Marc Hochberg⁷, ¹University of Pittsburgh Graduate School of Public Health, Pittsbugh, PA, ²University of California San Francisco, Orinda, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of Arizona College of Medicine, Tuscon, AZ, ⁵Northwestern University, Chicago, IL, ⁶Ohio State University, Columbus, OH, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: A recent international individual participant data (IPD) meta-analysis (n=10,723) reported a 35-37% increased mortality risk among individuals with painful knees (no radiographic OA) and…
Abstract Number: 1645 • ACR Convergence 2021
Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis
Joshua Baker¹, Bryant England², Michael George¹, Katherine Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Paul Monach⁶, Gary Kunkel⁷, Brian Sauer⁷, Bartlett Hamilton⁸, Carlos Hunter², Michael Duryee², Geoffrey Thiele² and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁶Brigham and Women's Hospital, Boston, MA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Nebraska, Omaha, NE
Background/Purpose: Adipokines are metabolic regulators and are associated with adverse outcomes in chronic conditions and among older adults. Elevations in one adipokine, adiponectin, have been…
Abstract Number: 0419 • ACR Convergence 2021
Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study
Gregory McDermott¹, Xiaoqing Fu², Claire Cook³, John Stone⁴, Yuqing Zhang⁵ and Zachary Wallace⁶, ¹Brigham and Women's Hospital, Brookline, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Newton, MA
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is associated with increased risk of end-stage renal disease (ESRD) and death. In most cases, circulating ANCA targeting…
Abstract Number: 1030 • ACR Convergence 2021
Critical Illness in Modern Rheumatology: Analysis of Admissions to Australian and New Zealand ICUs
Robyn Lambert¹, Shailesh Bihari², Mihir Wechalekar³, David Pilcher⁴ and Eliza Pontifex², ¹Flinders University, South Australia, Adelaide, Australia, ²Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, Australia, ³Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, ⁴Alfred Health, Melbourne, Australia
Background/Purpose: Patients with systemic rheumatic diseases (SRD) have an increased risk of admission to the Intensive Care Unit (ICU) relative to the general population, secondary…
Abstract Number: 1659 • ACR Convergence 2021
Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthritis After First Antidepressant Dispensing: Results from the Nationwide DANBIO Database
jens Pedersen¹, Lei Wang², Alma Pedersen², Kjeld Andersen³, Claus Sørensen³ and Torkell Ellingsen⁴, ¹Department of Medicine M, Section of Rheumatology, Svendborg Hospital, Odense University Hospital, Svendborg, Denmark, Odense, Denmark, ²Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Mental Health, Odense, Odense, Denmark, ⁴Rheumatology Research Unit, Department of Rheumatology C, Odense University Hospital, Odense, Denmark
Background/Purpose: Depression occurs with a prevalence of about 17% (95% confidence interval (CI): 10-24) in patients with RA (1) and both disorders may share common…
Abstract Number: 0429 • ACR Convergence 2021
Causes and Characteristics of Death in ANCA-Associated Vasculitis – A Large, Real-Life, Contemporary Cohort Analysis
Guy Katz¹, Claire Cook², Xiaoqing Fu¹, Hyon K. Choi³ and Zachary S. Wallace⁴, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA, ⁴Harvard Medical School, Boston, MA
Background/Purpose: Despite improvements, patients with ANCA-associated vasculitis (AAV) have a higher risk of death than the general population. Contemporary treatment is associated with high remission…
Abstract Number: 1032 • ACR Convergence 2021
Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity
Tiffany Taylor¹, Christine Anastasiou¹, Stephanie Rush¹, Laura Trupin², Maria Dall'Era³, Patricia Katz¹, Kamil Barbour⁴, Jinoos Yazdany¹ and Milena Gianfrancesco¹, ¹University of California San Francisco, San Francisco, CA, ²UC San Francisco, San Francisco, CA, ³University of California San Francisco, Corte Madera, CA, ⁴Centers for Disease Control, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Data indicate that minority populations are at higher…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].